BackOnco-Innovations Limited Overview

Onco-Innovations Limited EBIT

Latest ebit for ONCO.NE: $-12M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$3.03M
↓ 24.97% YoY

As of Jan 31, 2026

Annual EBIT (TTM)

-$11.72M

Trailing 12 months ending Jan 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Onco-Innovations Limited (ONCO.NE) FAQ

Onco-Innovations Limited (ONCO.NE) currently reports a EBIT of $-12M as of January 2026. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Onco-Innovations Limited's EBIT history and peer comparisons.

Onco-Innovations Limited's EBIT of $-12M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Onco-Innovations Limited reported $-12M in EBIT as of January 2026. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-12M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Onco-Innovations Limited, and consider following ONCO.NE for alerts when major investors trade the stock.

Onco-Innovations Limited is classified in the Healthcare sector. On EBIT, it currently shows $-12M versus a sector average near $1.9T. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ONCO.NE with unrelated industries.